Combining low-dose CBD (10 mg/kg) with standard IBD medications olsalazine or cyclosporine significantly improved colitis outcomes in mice beyond either treatment alone, without liver or kidney toxicity.
gastroenterologists, IBD patients, pharmaceutical researchers, integrative medicine practitioners
What the researchers found
In both acute and chronic colitis mouse models, combining low-dose CBD with olsalazine (50 mg/kg) or cyclosporine (2.5-5 mg/kg) significantly reduced disease activity index, MPO activity, and inflammatory cytokines while restoring colon length and GLP-1 levels. CBD monotherapy alone was inconclusive, but combinations were superior. No liver or kidney toxicity observed.
Why it matters
Current IBD treatments often have limited long-term efficacy and significant side effects. If CBD can enhance standard treatments at low doses without adding toxicity, it could meaningfully improve patient outcomes.
The numbers in context
CBD 10 mg/kg. Olsalazine 50 mg/kg. Cyclosporine 2.5-5 mg/kg. Combination: reduced DAI, MPO, inflammatory cytokines. Restored colon length and GLP-1 levels. No hepatic or renal toxicity on blood work.
How the study worked
DSS-induced acute and chronic colitis models in mice. Tested CBD (10 mg/kg) alone and in combination with olsalazine or cyclosporine. Assessed DAI, colon morphology, cytokines, chemokines, MPO, systemic inflammatory markers, GLP-1, hematology, and plasma biochemistry.
What this study cannot tell us
Mouse colitis model does not perfectly recapitulate human IBD. CBD dosing in mice may not translate directly to human doses. Short-term safety assessment — long-term toxicity unknown. Specific drug interactions not fully characterized.
How to read the evidence
Well-designed preclinical study with both acute and chronic colitis models and comprehensive safety assessment, but mouse model limits clinical translation.
When this study was published
2025 publication.
The bigger picture
This study supports a practical clinical approach: rather than relying on CBD as a standalone treatment (where evidence is inconclusive), using it as an adjunct to existing medications could enhance efficacy while keeping doses of both components low enough to minimize side effects.
Questions still open
- Would CBD-drug combinations show similar benefits in human IBD clinical trials?
- What is the optimal CBD dose for combination therapy in humans?
Common questions
Can CBD help with inflammatory bowel disease?
Is it safe to take CBD with IBD medications?
Read the original research
Cannabidiol Enhances the Therapeutic Efficacy of Olsalazine and Cyclosporine in a Murine Model of Colitis.
International journal of molecular sciences, 26(16)
Citation
Thapa, Dinesh; Patil, Mohan; Warne, Leon N; Carlessi, Rodrigo; Falasca, Marco. (2025). Cannabidiol Enhances the Therapeutic Efficacy of Olsalazine and Cyclosporine in a Murine Model of Colitis.. International journal of molecular sciences, 26(16). https://doi.org/10.3390/ijms26167913
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk
- Cannabis and IBS: Gut Health, Inflammation, and Symptom Relief
- Cannabis and Crohn's Disease: What Gastroenterology Research Shows